Valuation: OLIPASS Corporation

Market Cap 2.65TCr 1.73Cr 1.52Cr 1.4Cr 1.31Cr 2.45Cr 163.19Cr 2.51Cr 17Cr 6.5Cr 81Cr 6.5Cr 6.35Cr 279.66Cr P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 2.03TCr 1.33Cr 1.16Cr 1.07Cr 1Cr 1.88Cr 125.08Cr 1.92Cr 13Cr 4.98Cr 62Cr 4.98Cr 4.87Cr 214.36Cr EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
34,500
5 years 1,568
Extreme 1568
1,58,000
10 years 1,568
Extreme 1568
2,40,666.67
Manager TitleAgeSince
Chief Executive Officer 54 22/05/2025
Corporate Officer/Principal 34 28/11/2024
Comptroller/Controller/Auditor 67 31/03/2025
Director TitleAgeSince
Director/Board Member 54 28/11/2024
Director/Board Member 34 28/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-90.04% 90.91L
+0.33%+2.83%+62.37%+115.97% 5.53TCr
+0.82%+15.05%+74.28%+86.70% 5.19TCr
+1.36%+1.14%-14.06%-14.69% 2.28TCr
-1.04%+4.84%+1.61%+419.24% 2.26TCr
-0.18%+7.20%+28.56%-12.48% 1.74TCr
-1.10%+4.61%+29.38%-34.99% 1.61TCr
-3.35%+8.96%+135.18%+294.38% 1.4TCr
+2.89%+6.66%+27.11%+181.45% 1.34TCr
+1.31%+0.53%+27.21% - 1.23TCr
Average -1.29%-0.43%+37.16%+105.06% 2.26TCr
Weighted average by Cap. +0.24%+5.29%+46.86%+121.03%

Financials

2021 2022
Net sales 85Cr 6L 5L 4L 4L 8L 5.24Cr 8L 53.95L 20.88L 2.59Cr 20.86L 20.4L 8.98Cr 229.6Cr 14.97L 13.13L 12.1L 11.33L 21.24L 14Cr 21.68L 1.45Cr 56.27L 6.98Cr 56.22L 54.99L 24Cr
Net income -2.51TCr -1.64Cr -1.44Cr -1.32Cr -1.24Cr -2.33Cr -154.6Cr -2.37Cr -16Cr -6.16Cr -76Cr -6.15Cr -6.02Cr -264.95Cr -2.42TCr -1.58Cr -1.38Cr -1.27Cr -1.19Cr -2.24Cr -148.66Cr -2.28Cr -15Cr -5.92Cr -73Cr -5.92Cr -5.79Cr -254.76Cr
Net Debt -1.83TCr -1.19Cr -1.05Cr -96.39L -90.24L -1.69Cr -112.5Cr -1.73Cr -12Cr -4.48Cr -56Cr -4.48Cr -4.38Cr -192.8Cr -619.5Cr -40.39L -35.42L -32.65L -30.56L -57.31L -38Cr -58.5L -3.92Cr -1.52Cr -19Cr -1.52Cr -1.48Cr -65Cr
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
78
  1. Stock Market
  2. Stocks
  3. A244460 Stock